Latest Clinical Data on Weight Loss Drugs Metsera - MET-097 Om September 24, 2024, Metsera announced that its long-acting weight loss therapy, MET-097, achieved significant and lasting weight loss effects in a phase 1 clinical trial
Second, we have not considered several practical limitations and costs associated with increasing medication use, such as marketing and advocacy required to reach high rates of use
Reviews describe regenerative and protective actions, roles in skin regeneration, and modulation of multiple cellular pathways but this is largely mechanistic and preclinical work, not large human efficacy trials
References Micronutrient Information Center in-depth article on Immunity US Department of Health and Human Services, National Institutes of Health, National Institute of Allergy and Infectious Diseases, National Cancer Institute
These findings suggest a possible role for exogenous GLP-1R agonism on primary and metastatic thyroid tissues warranting further investigation